$TEM

Energy Vault (NRGV) director bought 27,472 shares at $3.88 each. Keurig Dr Pepper (KDP) director acquired 7,862 shares at $31.83. Welltower (WELL) director purchased 10,000 shares at $239.47-$242.06. American Assets (AAT) chairman bought 79,729 shares at $22.74-$22.89. Lumentum (LITE) exec sold 38,604 shares at $842.22-$860.05. Tempus AI (TEM) CEO sold 238,052 shares at $64.03-$70.58. CoreWeave (CRWV) CEO sold 307,692 shares at $88.31-$89.93. Illumina (ILMN) director sold 375,541 shares at $224.

Ark Invest's ARK Innovation ETF, managed by Cathie Wood, allocated $1.4B to three AI-related stocks: Tesla (TSLA) with a $595M position and $2,600 price target by 2029, Tempus AI (TEM) with a $402M position, and SpaceX (SPCX) with a $378M position. The ETF has $6.42B in assets under management.

Tempus AI CEO Eric Lefkofsky sold 11,848 shares for $827,856, with TEM stock up 33% in six months. Tempus reported Q2 2026 revenue of $382.5M, up 22% YoY but below estimates. Analysts lowered price targets but maintained a Buy rating.

LEFKOFSKY ERIC P (CEO and Chairman) sold 11,848 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $69.87 ($69.83–$70.58, $0.83M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

LEFKOFSKY ERIC P (CEO and Chairman) sold 238,152 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $68.39 ($64.03–$70.58, $16.29M total) across 30 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

A Delaware federal judge rejected Tempus AI's bid to dismiss Guardant Health's lawsuit alleging patent infringement. The case involves technology for analyzing cancer-related genetic data. Guardant Health claims Tempus AI violated its patents.

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

Cathie Wood's Ark Investment Management sold $4 million of Tempus AI (TEM) shares after a 30% surge. The Ark Innovation ETF (ARKK) gained 35.49% in 2023, outpacing the S&P 500. Wood remains bullish on AI, citing its potential to boost corporate profits and economic growth.

Fukushima Ryan (CEO, Data) sold 14,286 indirectly-held shares of Tempus AI, Inc. (TEM) at $70.00 ($1.00M total) on 2026-08-21 under a Rule 10b5-1 trading plan.

Personalis Inc. (PSNL) fell 6% after Craig-Hallum downgraded it to hold from buy, citing an unlikely higher bid than its announced sale to Tempus AI (TEM). Tempus shares also dropped 7.2%.